NCT05440838Recruiting
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
First-line treatment for patients with polycythemia vera, essential thrombocythemia, and pre-myelofibrosis is based on hydroxyurea or pegylated interferon. The objective of treatment is to prevent thrombotic complications and leukemic transformation. Despite overall good response rates, some patients do not respond to treatment and others lose their response over time. Both situations are associated with worse survival and there are to date no clear predictive factors for response although the existence of additional mutations seems unfavorable. In this exploratory study, we hypothesize that biological factors at diagnosis are associated with hematological response at 12 months. We will more specifically study the association between mutational profile, assessed by next-generation sequencing, and cytokine profile with hematological response. This study will help in identifying patients who will not respond to hydroxyurea or pegylated interferon and give the opportunity to try other treatments upfront, in the perspective of precision medicine. On the basic science side, this study will help in understanding the molecular and immunological factors involved in resistance to treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 10 Jun 2022
- Start date
- 17 May 2023
- Primary completion date
- 17 Feb 2027
- Lead sponsor
- University Hospital, Angers
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT05440838
What you commit to
- Study type: Observational
- Planned participants: 120
- From 17 May 2023 to the primary completion date, 17 Feb 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment.
Other illness
- Other on-going malignancy, including overt myelofibrosis.
Other
- Other treatment such as phlebotomy solely, ruxolitinib, anagrelide, or pipobroman.
Who the study is looking for
- Adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis.
- Indication for first-line treatment with hydroxyurea or pegylated interferon.
- Consent to participate.
- Affiliated to social security.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Angers Coordinator of this site? Confirm its status | Angers | France | Recruiting |
| Chu Brest Coordinator of this site? Confirm its status | Brest | France | Recruiting |
| CHU Nantes Coordinator of this site? Confirm its status | Nantes | France | Recruiting |
| CHU Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Recruiting |
| CHU Rennes Coordinator of this site? Confirm its status | Rennes | France | Recruiting |
| CHU Tours Coordinator of this site? Confirm its status | Tours | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.